SCHEMBL4218263

SCHEMBL4218263

CC(NC(=O)c1cc(C(N)=O)cc(N(C)S(C)(=O)=O)c1)c1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 19/20 0.62
BACE2 Q9Y5Z0 10/20 0.62
CTSD P07339 5/20 0.58
APP P05067 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3510372 1.00 BACE1 (0.62) BACE1BACE2CTSDAPP
SCHEMBL3510224 0.91 BACE1 (0.64) BACE1BACE2CTSDAPP
SCHEMBL3446306 0.91 BACE1 (0.64) BACE1BACE2CTSDAPP
SCHEMBL4206841 0.87 BACE2 (0.61) BACE1BACE2CTSDAPP
SCHEMBL13228791 0.87 BACE2 (0.61) BACE1BACE2CTSDAPP
SCHEMBL3686677 0.85 ALDH1A1 (0.60)
SCHEMBL8249481 0.82 BACE1 (0.88) BACE1BACE2CTSDAPP
SCHEMBL13316940 0.81 BACE1 (0.67) BACE1BACE2CTSDAPP
SCHEMBL2248494 0.81 BACE1 (0.71) BACE1BACE2
SCHEMBL3446848 0.80 BACE1 (0.77) BACE1BACE2CTSDAPP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7504420-B2 Compounds which inhibit beta-secretase activity and methods of use COMENTIS, INC. (US) 2009-03-17 US disclosed
US-20080207527-A1 Bicyclic Compounds Which Inhibit Beta-Secretase Activity and Methods of Use Thereof COMENTIS, INC. (US) 2008-08-28 US disclosed
US-20080176939-A1 COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF COMENTIS, INC. (US) 2008-07-24 US disclosed
EP-1797052-A1 BICYCLIC COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF COMENTIS, INC. (US) 2007-06-20 EP disclosed
US-20070117793-A1 Compounds Which Inhibit Beta-Secretase Activity and Methods of Use ZAPAQ, INC. (US) 2007-05-24 US disclosed
WO-2006034277-A1 BICYCLIC COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF COMENTIS, INC. (US) 2006-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117793-A1 Compounds Which Inhibit Beta-Secretase Activity and Methods of Use BACE1, BACE2, APP BACE1 1/4885BACE2 2/4885CTSD 31/4885
US-20080176939-A1 COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF BACE1, BACE2, APP BACE1 1/4885BACE2 2/4885CTSD 50/4885
US-20080207527-A1 Bicyclic Compounds Which Inhibit Beta-Secretase Activity and Methods of Use Thereof BACE1, BACE2, PSEN1 BACE1 1/4885BACE2 2/4885CTSD 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.